Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review.

Autor: Stanciu IM; Department of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania., Pirlog CF; Department of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania., Anghel AW; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania.; Department of Radiotherapy, Elias University Emergency Hospital, 011461 Bucharest, Romania., Parosanu AI; Department of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania., Olaru CM; Department of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania., Orlov-Slavu C; Department of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania., Iaciu IC; Department of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania., Popa AM; Department of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania., Vrabie RC; Department of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania., Nitipir C; Department of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania.
Jazyk: angličtina
Zdroj: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2023 Apr 01; Vol. 59 (4). Date of Electronic Publication: 2023 Apr 01.
DOI: 10.3390/medicina59040696
Abstrakt: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Following progression, no prospective randomized data exist to help guide second-line treatment. Moreover, there is a scarcity of data on rechallenge treatment strategies with another CDK4/6 inhibitor after prior limiting toxicity. We report a real-world experience of rechallenging with abemaciclib after the prior reaction of grade 4 liver toxicity to ribociclib, with high transaminases values of more than 27 times the upper limit of normal (ULN) and unexpected grade 3 neutropenia and diarrhea after a few months of abemaciclib. After two years of treatment, the patient had stable oncological disease, with normal complete blood count, hepatic enzymes, and a very good performance status. We believe that our clinical case, along with others gathered from all around the world, will help with the consolidation of an unmet clinical need to readjust the treatment after experiencing toxicity to CDK4/6 inhibitors.
Databáze: MEDLINE
Externí odkaz: